Concerns about the long-term safety and efficacy of glibenclamide(GLIB),a type 2 diabetes mellitus(T2DM)treatment,have been reported[1].Recent evidence indicates the gut microbiota composition significantly affects ho...Concerns about the long-term safety and efficacy of glibenclamide(GLIB),a type 2 diabetes mellitus(T2DM)treatment,have been reported[1].Recent evidence indicates the gut microbiota composition significantly affects host glucose metabolism and drugbioavailability,increasingthe efficacy of T2DM therapy[2].In this context,probiotic-drug coadministration,an emerging adjunct approach for treating metabolic diseases,improves therapeutic outcomes and ameliorates side effects[3].展开更多
基金supported by the National Natural Science Foundation of China(32525049).
文摘Concerns about the long-term safety and efficacy of glibenclamide(GLIB),a type 2 diabetes mellitus(T2DM)treatment,have been reported[1].Recent evidence indicates the gut microbiota composition significantly affects host glucose metabolism and drugbioavailability,increasingthe efficacy of T2DM therapy[2].In this context,probiotic-drug coadministration,an emerging adjunct approach for treating metabolic diseases,improves therapeutic outcomes and ameliorates side effects[3].
